Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA to Propose New NHI Pricing System with Innovation as Key Word
January 22, 2007
- Original Makers, GE Makers Must Cooperate in Case of Shortage: Taiyo Yakuhin
January 22, 2007
- JPA Concerned about Effects of Flat Sum System on Dispensing Services
January 22, 2007
- Kodak to Sell Health Group to Onex
January 22, 2007
- COMMENTARY／Acetaminophen, 1st Step Forward Toward Better Pediatric Pharmacotherapy
January 22, 2007
- Daiichi Pharm. Launches Sonazoid Ultrasound Contrast Agent
January 22, 2007
- REGULATORY NEWS IN BRIEF
January 22, 2007
- JSA to Propose Anti-stroke Measures
January 22, 2007
- STATISTICS／Population Declines for Second Year in a Row in 2006: Korosho
January 22, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 22, 2007
- Meiji Seika to Focus on Infectious Diseases, CNS, Generics
January 22, 2007
- Nippon Kayaku Focusing on R&D of Micelle-related Technology
January 22, 2007
- BUSINESS NEWS IN BRIEF
January 22, 2007
- Burgeoning Market for ARBs -Hot Battlefield for Megapharmas-Part 2
January 22, 2007
- Interest Growing in Exploratory Early Clinical Trials
January 22, 2007
- Preparation for Vaccine Development Project to Begin This Year: NIBIO
January 22, 2007
- Toyama to Focus on Development of T-705 as Anti-Flu Drug
January 22, 2007
- R&D NEWS IN BRIEF
January 22, 2007
- TOPICS／Milder Pollinosis Season Expected This Year↓
January 22, 2007
- SEMIANR
January 22, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…